Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine in a Multicenter Cohort of Nursing Home Residents Receiving Maintenance Hemodialysis

We recently reported that almost all maintenance hemodialysis (MHD) patients mount specific antibodies within a month of COVID-19 onset.1 However, evidence concerning the immunogenicity of SARS-CoV-2 vaccines in this immunodeficient population is scarce.2

Read the full article here

Related Articles